|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 202.76 USD | +2.11% |
|
-2.73% | -15.82% |
| 15/07 | Mizuho Adjusts Price Target on ResMed to $220 From $235, Maintains Outperform Rating | MT |
| 14/07 | Baird Adjusts ResMed Price Target to $217 From $225, Maintains Neutral Rating | MT |
Evolution of the Average Target: ResMed, Inc.
Evolution of the Target Price: ResMed, Inc.
Changes in Analyst Recommendations: ResMed, Inc.
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +27.01% | |||||
| +10.46% | |||||
| +20.78% | |||||
| +41.93% | |||||
| +68.45% | |||||
| +13.21% | |||||
| +32.81% | |||||
| +18.27% | |||||
| +10.19% | |||||
| +25.7% | |||||
| Average | +26.88% | |||||
| Weighted average by Cap. | +25.84% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Mizuho Securities | |
| Baird | |
| Citigroup | |
| Jefferies & Co. | |
| Jarden Research | |
| Wells Fargo Securities | |
| RBC Capital Markets | |
| KeyBanc Capital Markets | |
| Morgan Stanley | |
| Piper Sandler | |
| Stifel Nicolaus | |
| Morgans Financial | |
| Wolfe Research | |
| CICC Research | |
| JPMorgan Chase | |
| UBS | |
| Oppenheimer | |
| Needham & Co. | |
| Evans & Partners | |
| BofA Securities | |
| JMP Securities | |
| Goldman Sachs | |
| Macquarie | |
| J.P. Morgan Chase |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RMD Stock
- Consensus ResMed, Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition